Developer docs
API playgroundTry for free, no card

Search company profiles

Broadview Ventures

Full company profile

uuid0003dyw

Namestring
Broadview Ventures
Legal namestring
Broadview Ventures, Inc.
Company typeenum
Private
Founded yearint
2009
Descriptiontext

Broadview Ventures is a mission-driven venture capital firm founded in 2009 and backed by the Leducq Charitable Trust, a transatlantic foundation focused on cardiovascular disease. The firm invests exclusively in early-stage companies developing technologies for cardiovascular and neurovascular (stroke) indications, with a stated focus on seed and Series A rounds. Across its portfolio of 54 investments since inception, Broadview has targeted structural heart, heart failure, sleep apnea, hemostasis, and related modalities, sourcing opportunities globally across North America, Europe, Israel, Australia, and Canada.

The firm's core 'product' is structured seed and Series A capital combined with deep clinical and scientific domain support, leveraging the Leducq Foundation's global network of cardiovascular investigators. Longview Ventures, spun out in 2018, extends the firm's reach into Series B and later-stage follow-on financings, creating an integrated capital stack across early and growth stages for cardiovascular and stroke companies.

Economically, Broadview operates as a nonprofit-aligned investment vehicle rather than a conventional revenue-generating business. Capital is deployed from the foundation's endowment, and returns are realized through portfolio company exits and appreciation rather than management fees from external limited partners. The team is small and specialized, with recent senior promotions and advisory additions reinforcing succession and capacity for continued deal activity across the cardiovascular and stroke verticals.

Short descriptiontext

Broadview Ventures is a foundation-backed venture capital firm investing in early-stage (seed and Series A) cardiovascular and stroke technology companies globally, supporting 54 portfolio investments since 2009.

Operating statusenum
Operating
Ownership categoryenum
Headcount rangeband
11–50
akta.pro rankint
HeadquartersBoston, United States
HQ citystring
Boston
HQ countrystring
United States
HQ regionstring
North America
Markets served

Serves global market

Offices1 record

Each record includes

City, Country, Type, Description, Source

Keyword5 values
venture capital investing, cardiovascular technology, seed stage funding, medical device investment, biopharma investment
Industry2 codes
PRIMARYFSANAAAB
Early-Stage Venture Capital (Series A/B)
SECONDARYFSANAJAN
SDG / Thematic Sustainable Investment Funds
Financial & Insurance/Private Equity & Venture Capital/Impact / ESG & Sustainable Investment Funds
NAICS code2 codes
  • Portfolio Management and Investment Advice523940
  • Portfolio Management and Investment Advice52394
SIC code1 code
  • Investment Advice6282
Product category
Healthcare Venture Capital
Social media profiles1 record
GTM motion1 record

Each record includes

Type, Description, Source

Revenue model1 record
1Equity Investment Returns
TypeLicensing Royalties
Description

Broadview Ventures generates returns through equity investments in portfolio companies. Returns are realized through exits via acquisitions, IPOs, or subsequent financing rounds. The firm has had multiple successful exits including acquisitions by Edwards Lifesciences, Boston Scientific, Rocket Pharma, Mesoblast, Biogen, and others.

broadviewventures.org
Marketing channels3 records

Each record includes

Title, Type, Stage, Description, Source

Distribution channels1 record

Each record includes

Title, Type, Scope, Target buyer, Description, Source

Cost components5 values
Personnel, Operations, Technology or R&D, Marketing or Sales, Others
GTM typeB2B
B2B
Offering typeServices
Services
Brand1 record
1Longview Ventures
Description

An independent investment vehicle launched in 2018 by the Leducq Trust to make follow-on investments in Broadview portfolio companies that are poised to achieve significant value-creating milestones with their next financing round. Focuses on clinical-stage companies, Series B to Series C, as a complement to Broadview's Seed and Series A investments.

broadviewventures.org
Core offering1 text field

Broadview Ventures provides seed and early-stage equity investments in companies developing innovative technologies for the diagnosis and treatment of cardiovascular disease and stroke. Operating as the investment vehicle of the Leducq Charitable Trust, the firm makes first institutional financings (typically Seed and Series A) across Therapeutics, Devices, Diagnostics, and Digital Health, with a complementary follow-on vehicle (Longview Ventures) supporting later-stage portfolio companies through Series B and Series C rounds.

Differentiator
Functional benefit
Problem solved
Quantifiable outcome1 of 2 values shown
  • 54 companies invested since 2009
+1 more record
Product overview1 text field

Broadview Ventures operates as a mission-driven investment organization focused on accelerating the development of cardiovascular and stroke technologies. Founded in 2009 and supported by the Leducq Charitable Trust, the firm provides seed and early-stage equity financing to companies across two primary technology categories: MedTech (medical devices including transcatheter implants, AI-enabled monitoring systems, and pacing technologies) and BioPharma (therapeutics including small molecules, RNA-based drugs, and biologics for cardiovascular and metabolic diseases). The investment strategy leverages global thought leaders in cardiovascular science and medicine, with Longview Ventures serving as a complementary follow-on investment vehicle for later-stage portfolio companies.

Product and service4 records
1Broadview Ventures Seed and Series A Equity Investment
CategoryVenture Capital Investment
Description

Seed and early-stage equity financing for companies developing innovative cardiovascular and stroke technologies across Therapeutics, Devices, Diagnostics, and Digital Health; targeted at first institutional financings with active board involvement and strategic/operational support.

2Longview Ventures Follow-on Equity Investment
CategoryVenture Capital Investment
Description

Series B to Series C follow-on equity investments in Broadview Ventures portfolio companies that have achieved significant value-creating milestones; designed to complement Broadview's Seed and Series A focus.

3Broadview MedTech Investment Portfolio
CategoryInvestment Portfolio - Medical Devices
Description

Portfolio of medical device companies developing cardiovascular technologies including transcatheter heart failure treatment (Alleviant Medical), AI-enabled cardiac monitoring (Cardiosense), extravascular pacing systems (AtaCor Medical), and tricuspid regurgitation devices (CroíValve).

4Broadview BioPharma Investment Portfolio
CategoryInvestment Portfolio - Biopharmaceuticals
Description

Portfolio of biopharmaceutical companies developing cardiovascular and metabolic therapeutics including GIPR antagonists for obesity (Antag Therapeutics), OSA treatment (Mosanna Therapeutics), intracranial hemorrhage treatment (Alveron Pharma), and RNA-based heart failure therapeutics (HAYA Therapeutics).

Scale indicator3 records

Each record includes

Type, Value, Description, Source

Recent move7 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight5 records

Each record includes

Type, Description

Peers10 records
TypeBroad incumbent
Description

Healthcare-focused investment manager with broad life sciences and medical device coverage. Comparable to Broadview in its dedicated healthcare specialization and stage-agnostic approach, though substantially larger AUM and broader therapeutic scope.

TypeBroad incumbent
Description

Healthcare-dedicated investment firm spanning venture, growth, and credit across therapeutics, devices, and diagnostics. Comparable to Broadview in healthcare focus and global reach, but with much broader stage range and larger fund vehicles.

TypeDirect peer
Description

Early-stage life sciences venture firm focused on therapeutics. Highly comparable to Broadview in stage (seed/Series A), check size philosophy, and dedicated biotech focus, though Broadview adds a cardiovascular-only vertical plus devices and diagnostics.

TypeDirect peer
Description

Healthcare-focused investment manager across public and private markets. Comparable in therapeutic-area specialization and willingness to back early-stage clinical assets, though its mandate is broader and includes public equities.

TypeDirect peer
Description

Early-stage life sciences venture firm creating and seeding biotech companies. Closely comparable to Broadview in stage preference (seed/Series A), therapeutic focus, and company-building orientation, though not cardiology-exclusive.

TypeDirect peer
Description

European-based life sciences venture firm investing from seed through late stage. Comparable to Broadview in stage range, life sciences dedication, and European footprint, with overlapping cardiovascular exposure.

TypeDirect peer
Description

Early-stage life sciences venture firm focused on seed and Series A biotech. Comparable to Broadview in stage and life-sciences dedication; both build concentrated portfolios around platform technologies.

TypeBroad incumbent
Description

Healthcare-focused investment manager with crossover, private, and public equity strategies. Comparable in cardiovascular and therapeutic-area expertise, though it operates across stages and public/private with much larger capital base.

TypeOthers
Description

Strategic acquirer in structural heart and critical care, and prior acquirer of Broadview portfolio company CardiAQ. Relevant as a strategic acquirer/corporate venture participant in the cardiovascular innovation ecosystem where Broadview invests.

TypeOthers
Description

Major cardiovascular medtech incumbent and acquirer of Broadview portfolio company Apama. Relevant as a strategic exit partner and corporate venture participant overlapping Broadview's device investment universe.

Market position
Strengths5 records

Each record includes

Headline, Details, Source

Weaknesses5 records

Each record includes

Headline, Details, Source

Competitive moat5 records

Each record includes

Type, Details

Key risks5 records

Each record includes

Headline, Details, Source

Key highlights7 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Segment1 record

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile1 record

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
No
API detail
Has APIbool
No

Docs URL, Description

AI maturity
App detail

Has app

Feature2 records

Each record includes

Title, Differentiator, Description, Source

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles12 records

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

No data
No data
Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment88 records

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Broadview Ventures

Healthcare Venture Capitalbroadviewventures.org

Broadview Ventures is a foundation-backed venture capital firm investing in early-stage (seed and Series A) cardiovascular and stroke technology companies globally, supporting 54 portfolio investments since 2009.

What Broadview Ventures does

Broadview Ventures is a mission-driven venture capital firm founded in 2009 and backed by the Leducq Charitable Trust, a transatlantic foundation focused on cardiovascular disease. The firm invests exclusively in early-stage companies developing technologies for cardiovascular and neurovascular (stroke) indications, with a stated focus on seed and Series A rounds. Across its portfolio of 54 investments since inception, Broadview has targeted structural heart, heart failure, sleep apnea, hemostasis, and related modalities, sourcing opportunities globally across North America, Europe, Israel, Australia, and Canada.

The firm's core 'product' is structured seed and Series A capital combined with deep clinical and scientific domain support, leveraging the Leducq Foundation's global network of cardiovascular investigators. Longview Ventures, spun out in 2018, extends the firm's reach into Series B and later-stage follow-on financings, creating an integrated capital stack across early and growth stages for cardiovascular and stroke companies.

Economically, Broadview operates as a nonprofit-aligned investment vehicle rather than a conventional revenue-generating business. Capital is deployed from the foundation's endowment, and returns are realized through portfolio company exits and appreciation rather than management fees from external limited partners. The team is small and specialized, with recent senior promotions and advisory additions reinforcing succession and capacity for continued deal activity across the cardiovascular and stroke verticals.

Broadview Ventures firmographics

Firmographics
Name
Broadview Ventures
Legal name
Broadview Ventures, Inc.
Website
https://broadviewventures.org
Company type
Private
Founded year
2009
Operating status
Operating
Headcount range
11–50 employees
Short description
Broadview Ventures is a foundation-backed venture capital firm investing in early-stage (seed and Series A) cardiovascular and stroke technology companies globally, supporting 54 portfolio investments since 2009.
Ownership category
akta.pro rank

Broadview Ventures industry classification

Industry
Product category
Healthcare Venture Capital
NAICS
Portfolio Management and Investment Advice (523940), Portfolio Management and Investment Advice (52394)
SIC
Investment Advice (6282)
akta.pro industry
PRIMARYFSANAAAB
Early-Stage Venture Capital (Series A/B)
SECONDARYFSANAJAN
SDG / Thematic Sustainable Investment Funds
Financial & Insurance/Private Equity & Venture Capital/Impact / ESG & Sustainable Investment Funds

Keywords

  • Venture capital investing
  • Cardiovascular technology
  • Seed stage funding
  • Medical device investment
  • Biopharma investment

Where Broadview Ventures is headquartered

Location

Headquarters

HQ city
Boston
HQ country
United States
HQ region
North America

Offices1 record

Markets served

Broadview Ventures business model

Business model
GTM type
B2B
Offering type
Services
Cost components
Personnel, Operations, Technology or R&D, Marketing or Sales, Others

Revenue model

  1. Equity Investment Returns: Broadview Ventures generates returns through equity investments in portfolio companies. Returns are realized through exits via acquisitions, IPOs, or subsequent financing rounds. The firm has had multiple successful exits including acquisitions by Edwards Lifesciences, Boston Scientific, Rocket Pharma, Mesoblast, Biogen, and others.

Go-to-market motion1 record

Distribution channels1 record

Marketing channels3 records

Broadview Ventures product offering

Product offering

Core offering

Broadview Ventures provides seed and early-stage equity investments in companies developing innovative technologies for the diagnosis and treatment of cardiovascular disease and stroke. Operating as the investment vehicle of the Leducq Charitable Trust, the firm makes first institutional financings (typically Seed and Series A) across Therapeutics, Devices, Diagnostics, and Digital Health, with a complementary follow-on vehicle (Longview Ventures) supporting later-stage portfolio companies through Series B and Series C rounds.

Product overview

Broadview Ventures operates as a mission-driven investment organization focused on accelerating the development of cardiovascular and stroke technologies. Founded in 2009 and supported by the Leducq Charitable Trust, the firm provides seed and early-stage equity financing to companies across two primary technology categories: MedTech (medical devices including transcatheter implants, AI-enabled monitoring systems, and pacing technologies) and BioPharma (therapeutics including small molecules, RNA-based drugs, and biologics for cardiovascular and metabolic diseases). The investment strategy leverages global thought leaders in cardiovascular science and medicine, with Longview Ventures serving as a complementary follow-on investment vehicle for later-stage portfolio companies.

Differentiator

Problem solved

Functional benefit

Brands

  • Longview Ventures: An independent investment vehicle launched in 2018 by the Leducq Trust to make follow-on investments in Broadview portfolio companies that are poised to achieve significant value-creating milestones with their next financing round. Focuses on clinical-stage companies, Series B to Series C, as a complement to Broadview's Seed and Series A investments.

Products and services

  • Broadview Ventures Seed and Series A Equity Investment Seed and early-stage equity financing for companies developing innovative cardiovascular and stroke technologies across Therapeutics, Devices, Diagnostics, and Digital Health; targeted at first institutional financings with active board involvement and strategic/operational support.
  • Longview Ventures Follow-on Equity Investment Series B to Series C follow-on equity investments in Broadview Ventures portfolio companies that have achieved significant value-creating milestones; designed to complement Broadview's Seed and Series A focus.
  • Broadview MedTech Investment Portfolio Portfolio of medical device companies developing cardiovascular technologies including transcatheter heart failure treatment (Alleviant Medical), AI-enabled cardiac monitoring (Cardiosense), extravascular pacing systems (AtaCor Medical), and tricuspid regurgitation devices (CroíValve).
  • Broadview BioPharma Investment Portfolio Portfolio of biopharmaceutical companies developing cardiovascular and metabolic therapeutics including GIPR antagonists for obesity (Antag Therapeutics), OSA treatment (Mosanna Therapeutics), intracranial hemorrhage treatment (Alveron Pharma), and RNA-based heart failure therapeutics (HAYA Therapeutics).

Quantifiable outcome

  • 54 companies invested since 2009
  • +1 more outcomes

Companies that use Broadview Ventures

Customer profile

Segments1 record

Ideal customer profiles1 record

Broadview Ventures technology and API

Technology

Technology focussed No

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

Feature2 records

Broadview Ventures partnerships and signals

Strategic signal

Scale indicators3 records

Recent moves7 records

Expansion highlights5 records

Broadview Ventures competitors and assessment

Company assessment

Broad incumbents

  • Deerfield Management: Healthcare-focused investment manager with broad life sciences and medical device coverage. Comparable to Broadview in its dedicated healthcare specialization and stage-agnostic approach, though substantially larger AUM and broader therapeutic scope.
  • OrbiMed: Healthcare-dedicated investment firm spanning venture, growth, and credit across therapeutics, devices, and diagnostics. Comparable to Broadview in healthcare focus and global reach, but with much broader stage range and larger fund vehicles.
  • RA Capital Management: Healthcare-focused investment manager with crossover, private, and public equity strategies. Comparable in cardiovascular and therapeutic-area expertise, though it operates across stages and public/private with much larger capital base.

Direct peers

  • venBio: Early-stage life sciences venture firm focused on therapeutics. Highly comparable to Broadview in stage (seed/Series A), check size philosophy, and dedicated biotech focus, though Broadview adds a cardiovascular-only vertical plus devices and diagnostics.
  • HealthCor Partners: Healthcare-focused investment manager across public and private markets. Comparable in therapeutic-area specialization and willingness to back early-stage clinical assets, though its mandate is broader and includes public equities.
  • Atlas Venture: Early-stage life sciences venture firm creating and seeding biotech companies. Closely comparable to Broadview in stage preference (seed/Series A), therapeutic focus, and company-building orientation, though not cardiology-exclusive.
  • Sofinnova Partners: European-based life sciences venture firm investing from seed through late stage. Comparable to Broadview in stage range, life sciences dedication, and European footprint, with overlapping cardiovascular exposure.
  • 5AM Ventures: Early-stage life sciences venture firm focused on seed and Series A biotech. Comparable to Broadview in stage and life-sciences dedication; both build concentrated portfolios around platform technologies.

Others

  • Edwards Lifesciences (corporate venture): Strategic acquirer in structural heart and critical care, and prior acquirer of Broadview portfolio company CardiAQ. Relevant as a strategic acquirer/corporate venture participant in the cardiovascular innovation ecosystem where Broadview invests.
  • Boston Scientific (corporate venture): Major cardiovascular medtech incumbent and acquirer of Broadview portfolio company Apama. Relevant as a strategic exit partner and corporate venture participant overlapping Broadview's device investment universe.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat5 records

Key risks5 records

Key highlights7 records

Customer concentration

Broadview Ventures social profiles

Digital presence

Broadview Ventures financial estimates

Financial estimate

Revenue estimate

Valuation estimate

Broadview Ventures leadership team

Management profile

Number of profiles

Profiles12 records

Broadview Ventures funding detail

Funding detail

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

Broadview Ventures M&A and investment

M&A and investment

M&A

Investments88 records

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Broadview Ventures

What does Broadview Ventures do?

Broadview Ventures provides seed and early-stage equity investments in companies developing innovative technologies for the diagnosis and treatment of cardiovascular disease and stroke. Operating as the investment vehicle of the Leducq Charitable Trust, the firm makes first institutional financings (typically Seed and Series A) across Therapeutics, Devices, Diagnostics, and Digital Health, with a complementary follow-on vehicle (Longview Ventures) supporting later-stage portfolio companies through Series B and Series C rounds.

Is Broadview Ventures a public or private company?

Broadview Ventures is a private company. It is classified as nonprofit foundation owned and is currently operating.

When was Broadview Ventures founded?

Broadview Ventures was founded in 2009. It employs 11 to 50 people.

Where is Broadview Ventures based?

Broadview Ventures is headquartered in Boston, United States, in the North America region.

How does Broadview Ventures make money?

One revenue line is on record: equity Investment Returns.

Who are Broadview Ventures's main competitors?

Broad incumbents on record are Deerfield Management, OrbiMed and RA Capital Management. Direct peers are venBio, HealthCor Partners, Atlas Venture, Sofinnova Partners and 5AM Ventures. Others are Edwards Lifesciences (corporate venture) and Boston Scientific (corporate venture).

Does Broadview Ventures have an API?

No public API is recorded for Broadview Ventures.

What industry is Broadview Ventures in?

Broadview Ventures's product category is Healthcare Venture Capital. Its primary akta.pro industry code is FSANAAAB, Early-Stage Venture Capital (Series A/B), with a secondary code of FSANAJAN, SDG / Thematic Sustainable Investment Funds. Its NAICS code is 523940 and its SIC code is 6282.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales
Live signals
BioSpaceAlveron Pharma Announces Close of €5M Seed Extension Financing, led by Broadview Ventures, to Accelerate Breakthrough Therapy for Intracranial HaemorrhageAlveron Pharma closed a €5 million Series Seed extension financing led by Broadview Ventures to advance its drug OKL-1111 for intracranial haemorrhage. The drug reverses anticoagulants and platelet inhibitors, with administration within 10 minutes of a CT scan. The capital will accelerate development for further clinical studies.Business Wire BlogAlveron Pharma Announces Close of €5M Seed Extension Financing, led by Broadview Ventures, to Accelerate Breakthrough Therapy for Intracranial HaemorrhageAlveron Pharma closed a €5 million Series Seed extension financing led by Broadview Ventures to advance its drug OKL-1111 for intracranial haemorrhage. The drug aims to reverse anticoagulants and platelet inhibitors, with administration within 10 minutes of a CT scan. The funds will accelerate development for further clinical studies.NextdigitalhealthCorFlow Secures $48.6M to Advance Novel Diagnostic & Drug Delivery PlatformCorFlow Therapeutics AG, a medical device company developing a diagnostic and drug delivery platform for microvascular obstruction after heart attacks, raised €44 million ($48.6 million) in a Series B round led by Panakes Partners and Broadview Ventures. The capital will fund the MOCA II pivotal study of its CoFITM System in Europe and the US, plus a study on adaptive platform therapy.Clinical Trials ArenaCorFlow secures $48.5m for microvascular obstruction detection deviceCorFlow Therapeutics secured $48.5 million in Series B funding to advance its microvascular obstruction detection device through a pivotal MOCA II study in the US and Europe. The financing, co-led by Broadview Ventures and Panakes Partners, will support trials evaluating the CoFI system's diagnostic accuracy and therapeutic delivery capabilities for heart attack patients.Pulse 2.0IsomAb Closes £7.5 Million To Develop Isoform-Specific Disease Modifying Antibody TreatmentIsomAb closed a £7.5 million seed round led by Broadview Ventures, with SCVC and MEIF participation. The funding will advance pre-clinical development of its lead antibody ISM-001 for peripheral ischaemia, targeting VEGF-A165b in patients with metabolic syndrome and Type II diabetes.BusinessCloudSpinout develops treatment for diabetics at risk of amputationIsomAb, a University of Nottingham spinout, raised £7.5 million to develop an antibody that inhibits VEGF-A165b, a protein blocking angiogenesis in diabetics with peripheral arterial disease. The funding, led by Broadview Ventures, will support further studies before clinical trials. The company's previous venture, Exonate, has completed its first clinical trial.InsidermediaSpin-out raises £7.5m in Broadview-led funding roundUniversity of Nottingham spin-out IsomAb has raised £7.5m in a funding round led by Broadview Ventures to support further studies for its novel treatment of peripheral arterial disease in diabetics. The capital, also backed by Mercia and SCVC, will enable the company to prepare for clinical trials targeting the VEGF-A165b protein.PR NewswireIsomAb Announces Close of £7.5 Million Financing to Accelerate Lead Candidate for Treatment of Peripheral Arterial DiseaseIsomAb Ltd, a UK-based biotechnology company, announced the closing of a £7.5 million Seed financing round led by Broadview Ventures to advance the pre-clinical development of its lead antibody ISM-001 for treating peripheral arterial disease. The funding also involves participation from existing investor SCVC and the MEIF Proof of Concept & Early Stage Fund. This financing aims to support IsomAb's novel program targeting patients with metabolic syndrome and Type II diabetes, highlighting the significance of addressing an unmet medical need in cardiovascular health.IsomabIsomAb Announces Close of £7.5 Million Financing to Accelerate Lead Candidate – IsomabIsomAb Ltd, a UK-based biotechnology company, closed a £7.5 million Seed financing round on February 20, 2024, led by Broadview Ventures with support from SCVC and the MEIF Proof of Concept & Early Stage Fund. The financing will advance the pre-clinical development of IsomAb's lead antibody, ISM-001, which aims to treat peripheral arterial disease. This investment emphasizes the potential for developing novel treatments for vascular disease, addressing a significant unmet medical need worldwide.